Integrated BioPharma (INBP) director Damon DeSantis granted 50,000 stock options

Rhea-AI Filing Summary

INTEGRATED BIOPHARMA INC director and 10% owner Damon DeSantis received a stock option grant covering 50,000 shares of common stock. The options carry an exercise price of $0.2000 per share and expire on June 24, 2036. Following this grant, DeSantis holds options for 50,000 shares directly. The award vests in four equal installments of 12,500 options on each of September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, meaning he can exercise portions of the grant over time as they vest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider DeSantis Damon

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option shares granted: 50,000 shares Exercise price: $0.2000 per share Shares underlying options: 50,000 shares +3 more

6 metrics

Option shares granted 50,000 shares Stock Option (Right to Buy) grant on June 24, 2026

Exercise price $0.2000 per share Conversion or exercise price of granted options

Shares underlying options 50,000 shares Underlying common stock tied to the option grant

Post-grant derivative holdings 50,000 derivative shares Total shares following transaction reported as derivative

Option expiration date June 24, 2036 Expiration date of the stock option award

Vesting installments 4 installments of 12,500 options Vesting on Sept 30 2026, Dec 31 2026, Mar 31 2027, Jun 30 2027

Key Terms

Stock Option (Right to Buy), conversion or exercise price, expiration date, vest and become exercisable, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

conversion or exercise price financial

"conversion_or_exercise_price: 0.2000"

expiration date financial

"expiration_date: 2036-06-24T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

vest and become exercisable financial

"The stock options vest and become exercisable in four equal installments"

derivative securities financial

"derivativeTransactionCount: 1, derivative transaction type"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 12:07 PM Accepted by SEC EDGAR 06/25/2026 - 12:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DeSantis Damon

(Last) (First) (Middle)

109 SE 5TH AVENUE

SECOND FLOOR

(Street)

DELRAY BEACH FLORIDA 33483

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTEGRATED BIOPHARMA INC [ INBP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$0.2	06/24/2026		A		50,000		(1)	06/24/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

1. The stock options vest and become exercisable in four equal installments (12,500 stock options each) on each of September 30, 2026, December 31, 2026, March 31, 2027 and June 30, 2027.

	/S/ Damon DeSantis	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did INBP director Damon DeSantis report on this Form 4?

Damon DeSantis reported receiving a stock option grant for 50,000 shares of Integrated BioPharma common stock. The options are a compensation-related award, not an open-market stock purchase or sale, and give him the right to buy shares at a fixed exercise price in the future.

What is the exercise price of Damon DeSantis’s new INBP stock options?

The granted stock options have an exercise price of $0.2000 per share. This means DeSantis can buy Integrated BioPharma common stock at $0.2000 per share once the options vest and before they expire, regardless of the market price at that time.

How many INBP shares are covered by Damon DeSantis’s new option award?

The option award covers 50,000 shares of Integrated BioPharma common stock. After this grant, the Form 4 shows DeSantis holding derivative securities for 50,000 underlying shares directly, all tied to this single option grant reported in the filing.

When do Damon DeSantis’s INBP stock options vest according to the Form 4?

The options vest in four equal tranches of 12,500 each. Vesting dates are September 30, 2026, December 31, 2026, March 31, 2027, and June 30, 2027, allowing DeSantis to exercise portions of the grant progressively over this period.

When do Damon DeSantis’s INBP stock options expire?

The stock options reported in the Form 4 expire on June 24, 2036. DeSantis must wait for each portion to vest but also exercise any vested options before this expiration date, or they will lapse and no longer be exercisable.

Is Damon DeSantis’s Form 4 transaction a market buy or sell of INBP shares?

No, the Form 4 shows a grant of stock options, coded “A” for award, not a market trade. It is a compensation-related acquisition of derivative securities, giving a future right to buy shares rather than an immediate stock purchase or sale.